GAMMA Investing’s Mineralys Therapeutics MLYS Stock Holding History

GAMMA Investing’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$23.2K	Buy	925 +410	+80%	+$11.2K	﹤0.01%	2854
2026 Q2	$13.9K	Buy	515 +41	+9%	+$1.12K	﹤0.01%	3039
2026 Q1	$12.8K	Buy	474 +23	+5%	+$675	﹤0.01%	2937
2025 Q4	$16.4K	Buy	451 +15	+3%	+$602	﹤0.01%	2718
2025 Q3	$16.5K	Sell	436 -1	-0.2%	-$22	﹤0.01%	2616
2025 Q2	$5.91K	Sell	437 -119	-21%	-$1.72K	﹤0.01%	3057
2025 Q1	$8.83K	Buy	556 +465	+511%	+$5.35K	﹤0.01%	2808
2024 Q4	$1.12K	Buy	91 +16	+21%	+$209	﹤0.01%	3392
2024 Q3	$908	Buy	+75	New	+$908	﹤0.01%	3282

Other funds holding MLYS

Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return

GAMMA Investing's MLYS Position: Q3 2026 in Review

GAMMA Investing increased its Mineralys Therapeutics (MLYS) stake by 80% in Q3 2026, buying an estimated $11.2K and bringing the position to 925 shares worth $23.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2854.

GAMMA Investing first reported a position in MLYS in Q3 2024 and has held it in 9 quarters since. 14 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

GAMMA Investing held 925 shares of Mineralys Therapeutics worth $23.2K as of Q3 2026.
GAMMA Investing bought 410 Mineralys Therapeutics shares in Q3 2026, an estimated $11.2K.
Mineralys Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2854 holding.
GAMMA Investing first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 9 quarters since.
14 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.